Introduction of whole genome sequencing as NHS standard of care for glioma patients in two neurosurgical oncology centres: West Midlands.

ABSTRACT:

Background

The challenges of introducing Whole Genome Sequencing (WGS) as NHS standard of care for patients with glioma are reviewed.

Methods

Patients undergoing glioma surgery with WGS sampling were identified retrospectively from WGS reports between 01/01/2022-30/12/2023. Data including demographics, integrated molecular diagnosis, time through critical pathway steps per calendar quarter (Q) and WGS variants were captured from electronic health records.

Results

146 glioma samples were analysed. 91% of patients underwent craniotomy and 1 cm³ tumour sampled for WGS, with median tumour content (MTC) of 69.5% (IQR + /- 30.5). The remainder underwent stereotactic needle biopsy, and one core sampled for WGS, with MTC of 73% (IQR + /- 19%). Median time from tumo

SUBMITTER: Wykes V 

PROVIDER: S-EPMC12606122 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature